Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
MLYS Stock Forecast 2025-2026
$38.50
Current Price
$3.05B
Market Cap
Buy 8
Hold 1
Sell 0
Wall St Analyst Ratings
Distance to MLYS Price Targets
+45.5%
To High Target of $56.00
+32.5%
To Median Target of $51.00
+9.1%
To Low Target of $42.00
MLYS Price Momentum
-10.7%
1 Week Change
+1.3%
1 Month Change
+191.4%
1 Year Change
+212.8%
Year-to-Date Change
-19.2%
From 52W High of $47.65
+367.2%
From 52W Low of $8.24
📊 TOP ANALYST CALLS
Did MLYS Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Mineralys is one of their latest high-conviction picks.
Latest MLYS Stock Price Targets & Analyst Predictions
Based on our analysis of 8 Wall Street analysts, MLYS has a bullish consensus with a median price target of $51.00 (ranging from $42.00 to $56.00). The overall analyst rating is N/A (N/A/10). Currently trading at $38.50, the median forecast implies a 32.5% upside. This outlook is supported by 8 Buy, 1 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Matthew Caufield at HC Wainwright & Co., projecting a 45.5% upside. Conversely, the most conservative target is provided by Matthew Caufield at HC Wainwright & Co., suggesting a 9.1% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
MLYS Analyst Ratings
8
Buy
1
Hold
0
Sell
MLYS Price Target Range
Low
$42.00
Average
$51.00
High
$56.00
Current: $38.50
Latest MLYS Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for MLYS.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Nov 12, 2025 | HC Wainwright & Co. | Matthew Caufield | Buy | Maintains | $56.00 |
| Nov 11, 2025 | Wells Fargo | Mohit Bansal | Overweight | Maintains | $55.00 |
| Oct 30, 2025 | HC Wainwright & Co. | Matthew Caufield | Buy | Maintains | $52.00 |
| Sep 11, 2025 | Wells Fargo | Mohit Bansal | Overweight | Maintains | $50.00 |
| Sep 9, 2025 | Goldman Sachs | Richard Law | Buy | Maintains | $52.00 |
| Sep 8, 2025 | HC Wainwright & Co. | Matthew Caufield | Buy | Reiterates | $42.00 |
| Sep 3, 2025 | Jefferies | Dennis Ding | Hold | Maintains | $26.00 |
| Aug 28, 2025 | B of A Securities | Greg Harrison | Buy | Maintains | $43.00 |
| Aug 13, 2025 | HC Wainwright & Co. | Matthew Caufield | Buy | Reiterates | $42.00 |
| Jun 17, 2025 | HC Wainwright & Co. | Matthew Caufield | Buy | Reiterates | $42.00 |
| Jun 11, 2025 | Jefferies | Dennis Ding | Hold | Initiates | $15.00 |
| May 13, 2025 | HC Wainwright & Co. | Matthew Caufield | Buy | Reiterates | $42.00 |
| Apr 2, 2025 | HC Wainwright & Co. | Matthew Caufield | Buy | Maintains | $42.00 |
| Mar 10, 2025 | HC Wainwright & Co. | Matthew Caufield | Buy | Reiterates | $30.00 |
| Feb 24, 2025 | Guggenheim | Seamus Fernandez | Buy | Reiterates | $N/A |
| Feb 13, 2025 | HC Wainwright & Co. | Matthew Caufield | Buy | Reiterates | $30.00 |
| Feb 13, 2025 | Goldman Sachs | Richard Law | Buy | Maintains | $24.00 |
| Nov 12, 2024 | HC Wainwright & Co. | Matthew Caufield | Buy | Reiterates | $30.00 |
| Oct 31, 2024 | HC Wainwright & Co. | Matthew Caufield | Buy | Reiterates | $30.00 |
| Aug 15, 2024 | HC Wainwright & Co. | Matthew Caufield | Buy | Reiterates | $30.00 |
Mineralys Therapeutics, Inc. (MLYS) Competitors
The following stocks are similar to Mineralys based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Mineralys Therapeutics, Inc. (MLYS) Financial Data
Mineralys Therapeutics, Inc. has a market capitalization of $3.05B with a P/E ratio of -10.5x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of -42.1%.
Valuation Metrics
Market Cap
$3.05B
Enterprise Value
$2.49B
P/E Ratio
-10.5x
PEG Ratio
0.2x
Price/Sales
N/A
Growth & Margins
Revenue Growth (YoY)
N/A
Gross Margin
N/A
Operating Margin
0.0%
Net Margin
0.0%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+19.5%
Current Ratio
25.5x
Debt/Equity
0.0x
ROE
-42.1%
ROA
-26.5%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Mineralys Therapeutics, Inc. (MLYS) Business Model
About Mineralys Therapeutics, Inc.
What They Do
Develops therapies for cardiovascular and renal diseases.
Business Model
Mineralys Therapeutics focuses on the discovery and development of innovative therapies that target hormone activity to treat cardiovascular and renal diseases. The company collaborates with research institutions and pharmaceutical partners, generating revenue through partnerships and potentially lucrative drug development pipelines addressing unmet medical needs.
Additional Information
By leveraging cutting-edge research and advancing precision medicine, Mineralys Therapeutics aims to transform treatment paradigms in healthcare. Their commitment to addressing complex health challenges positions them as a significant player in the biotechnology and healthcare sectors.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
51
CEO
Mr. Jon Congleton
Country
United States
IPO Year
2023
Website
mineralystx.comMineralys Therapeutics, Inc. (MLYS) Latest News & Analysis
Featured Analysis
Powered by
Zacks Investment Research
Wall Street Analysts Think Mineralys Therapeutics, Inc. (MLYS) Could Surge 27.55%: Read This Before Placing a Bet
The mean of analysts' price targets for Mineralys Therapeutics, Inc. (MLYS) points to a 27.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Dec 05, 2025
By Zacks Equity Research
Tale of the Tape
Latest News
Quick Summary
Findell Capital Management acquired 250,000 shares of MLYS worth $9.5 million in Q3, establishing a new position after holding no shares in the previous quarter.
Why It Matters
Findell Capital Management's $9.5 million investment in MLYS signals confidence in the company's potential, which may influence market perception and drive stock interest.
Source: The Motley Fool
Market Sentiment:
Positive
Quick Summary
Mineralys Therapeutics (Nasdaq: MLYS) granted a stock option award for 146,000 shares to a new non-executive employee on Nov. 24, 2025, as part of their compensation strategy.
Why It Matters
The stock option grant may indicate confidence in future growth and talent acquisition, potentially impacting share performance and investor sentiment regarding Mineralys' prospects.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Mineralys Therapeutics, Inc. (MLYS) will hold its Q3 2025 earnings call on November 10, 2025, at 4:30 PM EST, featuring key company executives and analysts from various firms.
Why It Matters
Mineralys Therapeutics' Q3 earnings call signals potential insights into financial performance and strategic direction, influencing investor sentiment and stock valuation.
Source: Seeking Alpha
Market Sentiment:
Neutral
Mineralys Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
26 days ago
Quick Summary
A New Drug Application for lorundrostat is expected in late 2025/Q1 2026. Enrollment in the Explore-OSA trial is complete, with topline results due in Q1 2026. Conference call scheduled for today at 4:30 p.m. ET.
Why It Matters
The timeline for lorundrostat's NDA and upcoming trial results can influence stock performance, investor sentiment, and market positioning for the company involved.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Mineralys Therapeutics presented clinical data for lorundrostat at ASN Kidney Week 2025, focusing on hypertension and related conditions. The trial is part of their Phase 3 program.
Why It Matters
The presentation of pivotal trial data for lorundrostat by Mineralys Therapeutics could influence stock performance, reflecting market confidence in their hypertension treatment pipeline and potential revenue growth.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Mineralys Therapeutics will present late-breaking Phase 2 trial data on lorundrostat for hypertension and CKD at ASN Kidney Week 2025, with Phase 3 data featured in top medical journals.
Why It Matters
Positive Phase 2 trial results for lorundrostat could indicate a promising treatment for hypertension and CKD, potentially boosting Mineralys Therapeutics' stock value and market position.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About MLYS Stock
What is Mineralys Therapeutics, Inc.'s (MLYS) stock forecast for 2026?
Based on our analysis of 8 Wall Street analysts, Mineralys Therapeutics, Inc. (MLYS) has a median price target of $51.00. The highest price target is $56.00 and the lowest is $42.00.
Is MLYS stock a good investment in 2026?
According to current analyst ratings, MLYS has 8 Buy ratings, 1 Hold ratings, and 0 Sell ratings. The stock is currently trading at $38.50. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for MLYS stock?
Wall Street analysts predict MLYS stock could reach $51.00 in the next 12 months. This represents a 32.5% increase from the current price of $38.50. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Mineralys Therapeutics, Inc.'s business model?
Mineralys Therapeutics focuses on the discovery and development of innovative therapies that target hormone activity to treat cardiovascular and renal diseases. The company collaborates with research institutions and pharmaceutical partners, generating revenue through partnerships and potentially lucrative drug development pipelines addressing unmet medical needs.
What is the highest forecasted price for MLYS Mineralys Therapeutics, Inc.?
The highest price target for MLYS is $56.00 from Matthew Caufield at HC Wainwright & Co., which represents a 45.5% increase from the current price of $38.50.
What is the lowest forecasted price for MLYS Mineralys Therapeutics, Inc.?
The lowest price target for MLYS is $42.00 from Matthew Caufield at HC Wainwright & Co., which represents a 9.1% increase from the current price of $38.50.
What is the overall MLYS consensus from analysts for Mineralys Therapeutics, Inc.?
The overall analyst consensus for MLYS is bullish. Out of 8 Wall Street analysts, 8 rate it as Buy, 1 as Hold, and 0 as Sell, with a median price target of $51.00.
How accurate are MLYS stock price projections?
Stock price projections, including those for Mineralys Therapeutics, Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: December 7, 2025 1:39 AM UTC